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Abstract: Inflammation disturbs biochemical pathways involved in homeostasis of the endothelium. Research has estab-
lished  clear  links  between  inflammatory  mediators,  particularly  C-reactive  protein  and  tumour  necrosis  factor  alpha,  
endothelial  dysfunction,  and  atherosclerosis.  Endothelial  dysfunction  and  atherosclerosis  may  be  subclinical  at  early 
stages, and thus the ability to detect them with non-invasive techniques is crucially important, particularly in populations 
at increased risk for cardiovascular disease, such as those with rheumatoid arthritis. This may allow the identification of 
interventions that may reverse  these processes early on. One of  the best non-pharmacological interventions that may 
achieve this is physical activity. This review explores the associations between inflammation, endothelial dysfunction,  
and atherosclerosis and discusses the role of exercise in blocking specific pathways in the inflammation, endothelial dys-
function - atherosclerosis network. 
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INTRODUCTION 
  The  endothelium  is  now  regarded  as  a  dynamic  organ 
lining the entire vascular system. It is responsible for many 
atheroprotective functions via its regulation of the immune 
response, fibrinolysis, coagulation, as well as multiple other 
functions  related  to  vascular  growth,  vasoprotection,  and 
vasoregulation.  Disruption  of  normal  endothelial  function 
impedes  its  protective  effects  on  vascular  homeostasis,  an 
early event characterizing the development of cardiovascular 
disease (CVD) [1-3]. Most importantly, endothelial dysfunc-
tion and the early stages of CVD may occur in the absence of 
any clinical symptoms. Hence, finding methods for assessing 
vascular dysfunction during the early stages of the disease is 
important, particularly in patient groups at high  CVD risk 
[4].  
  Rheumatoid arthritis (RA) is the most common chronic 
inflammatory arthritis characterized by symptoms and signs 
of joint and systemic inflammation, joint destruction, body 
composition alterations, and physical disability. It also asso-
ciates  with  high  CVD  morbidity  and  mortality,  which  are  
not fully explained by the presence of traditional CVD risk 
factors [5-8]. In RA, increased local (synovial) and systemic 
expression  of  specific  inflammatory  mediators  may  have 
detrimental  effects  on  the  endothelium  by  enhancing  bio-
chemical processes leading to its dysfunction and eventually  
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the  development  of  atherosclerosis  [2,  9].  Indeed,  the  
inflammatory pathways involved in the pathogenesis of RA 
and atherosclerosis share many characteristics [10]. Inflam-
mation  in  RA  is  often  evaluated  by  measuring  the  acute 
phase reactant C-reactive protein (CRP) and/or the erythro-
cyte sedimentation rate (ESR), which, in combination with 
other clinical markers (e.g. disease activity or X-ray scores), 
are used to assess the disease state and response to treatment 
[11]. The acute phase response is attributed to increased lev-
els of pro-inflammatory cytokines, such as tumour necrosis 
factor  alpha  (TNF-alpha)  and  interleukin-6  (IL-6)  [10], 
which are individually or synergistically involved in many 
other  disease  processes,  including  joint  destruction  [12]  
altered  body  composition  [13],  and  changes  in  vascular  
homeostasis [14, 15].  
INFLAMMATION  AND  ENDOTHELIAL  DYSFUNC-
TION  
  The endothelium controls vascular function by releasing 
vasoactive  factors  such  as  nitric  oxide  (NO),  prostacyclin 
(PGI2),  and  endothelin-1  (ET-1).  Endothelial  dysfunction 
occurs when the balance between these vasoactive factors is 
disturbed. The down-regulation of endothelial NO synthase 
(eNOS) plays an important role in this process [16]. Altered 
endothelial homeostasis due to the disturbed NO production is 
characterized by diminished endothelium-dependent dilation 
and increased expression of adhesion molecules, as well as 
changes in endothelial cell phenotype and increased endothe-
lial  permeability  [17].  Such  changes  in  the  structure  and 
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initial stages in the pathogenesis of atherosclerosis and CVD 
[18].  
  Several  studies  have  established  a  strong  link  between 
inflammation  and  endothelial  dysfunction.  In  vitro,  CRP 
modulates eNOS activity of human endothelial cells [19, 20] 
via uncoupling eNOS and subsequently increasing superox-
ide anions (oxidative stress) from NADPH oxidase [21]. As 
a  result,  phosphorylation  of  eNOS  is  decreased,  and  this  
subsequently reduces bioavailability of NO [22]. Apart from 
NO,  CRP  upregulates  the  expression  of  ET-1  which  is  a 
vasoconstrictor  [23].  Studies  also  reveal  a  direct  effect  of 
TNF-alpha  on  dowregulating  the  expression  of  eNOS  and 
diminishing endothelial NO [15]. TNF-alpha downregulates 
at  the  same  time  enzymatic  activities  of  eNOS  and 
argininosuccinate  synthetase  (regulator  of  citrulline/NO 
cycle) [24] and induces an increase in mRNA degradation of 
both eNOS and neuronal NO synthase promoting vasocon-
striction  [25].  In  addition,  by  activating  NADPH  oxidase, 
TNF-alpha stimulates the generation of reactive oxygen spe-
cies  within  the  endothelial  environment  further  impairing 
NO-mediated vasodilation [26]. Apart from inhibition of NO 
production, TNF-alpha may also be responsible for the re-
duction in the bioavailability of NO [27]. This is perhaps the 
main reason why TNF-alpha inhibition is directly linked to 
improved endothelial function in both RA [28] and non-RA 
populations [29].  
  Endothelial function and morphology are reported to be 
significantly worse in RA compared to healthy controls and 
this is attributed in large part to the high-grade inflammatory 
state of RA [30, 31]; in fact, acute inflammation (e.g. in re-
sponse  to  immunization)  and  low-grade  chronic  systemic 
inflammation (detected using high sensitivity CRP assays) in 
healthy  individuals  has  been  directly  linked  with  arterial 
stiffness and vascular dysfunction [32, 33]. However, despite 
this  biologically  plausible  link  between  inflammation  and 
vascular  dysfunction,  there  are  still  some  controversies  
and inconsistent results in RA [34, 35], where some studies 
report a lack of association between systemic inflammatory 
load and endothelial function [36-38]. This may be attributed 
to  different  methodological  approaches  (e.g.  using  small, 
diverse patient populations cross-sectionally, or even smaller 
populations longitudinally but with short  time courses), or 
lack of sufficient statistical power and no correction for mul-
tiple  potential  confounders  (e.g.  age  and  many  CVD  risk 
factors). The link between inflammation and vascular func-
tion appears to be more consistently demonstrated in homo-
geneous RA samples, such as young patients, patients with 
new onset RA and without established CVD [31, 39]. Vascu-
lar function may progressively deteriorate during the course 
of RA [40]. Hence, RA patients with long disease duration 
may already have significantly impaired endothelial function 
at the time of assessment, irrespective of disease “current” 
activity. Given the fluctuations in inflammation characteris-
tic of RA, it might be that longstanding, though intermittent, 
inflammatory  insult  to  the  endothelium  is  of  more  impor-
tance to vascular function in  RA than the  current  level of 
inflammation [41]. Studies that took into account long-term 
inflammatory burden have been able to demonstrate associa-
tions between this and vascular function [36, 39].  
INFLAMMATION AND ATHEROSCLEROSIS 
  Endothelial cell dysfunction, evident as NO deficiency, 
appears  to  be  amongst  the  earliest  processes  involved  in 
atherosclerosis. Reduction of NO bioavailability disrupts the 
balance of the vasoactive factors, which allow ET-1 levels to 
increase  and  cause  vasoconstriction  [16].  Along  with  the 
biochemical  mediators  of  endothelial  function,  mechanical 
forces and in particular, shear stress are also responsible for 
altering the phenotype of endothelial cells. Shear stress is the 
tangential stress that is applied to the artery wall and induces 
distension of the arteries; it is long-known that atheroscle-
rotic  lesions originate mainly in  areas of low shear stress, 
where flow is disturbed [42, 43]. In these areas, endothelial 
cells promote a pro-atherogenic phenotype [44], enhancing 
both the local selectivity of plaque formation, as well as ves-
sel wall remodeling, which, in turn, affects plaque vulner-
ability [45].  
  At the  initial stages of atherosclerosis,  leukocytes, par-
ticularly monocytes, progressively transmigrate through the 
endothelium with the help of monocyte chemoattractant pro-
tein 1 (MCP-1) and IL-8 [14]. Atherosclerosis progresses via 
the differentiation of monocytes into macrophages that retain 
low-density lipoproteins  and become foam cells. Increased 
permeability  of  RA  endothelial  cells  further  enhances  the 
entry of low-density lipoproteins and further promotes this 
cascade of events [46]. It has now been well-established that 
inflammation is involved in all phases of the atherothrom-
botic  processes  [2].  Whereas  MCP-1  and  IL-8  regulate 
monocyte transmigration, IL-8 can be upregulated in endo-
thelial cells by CRP via the NF-kB pathway [47]. CRP can 
also increase the expression of macrophage colony stimulat-
ing  factor  (M-CSF),  responsible  for  the  differentiation  of 
monocytes  into  macrophages.  Subsequently,  macrophage 
proliferation increases, thereby enhancing the progression of 
atherosclerosis via the promotion of the formation of foam 
cells [48]. An alternative effect of CRP is to destabilize the 
atheromatous  plaque  at  later  stages  of  atherosclerosis,  by 
upregulation of matrix metalloproteinases [49] which causes 
weakening  of  the  plaque’s,  fibrous  cap.  Apart  from  the 
above effects of CRP on these individual steps of atheroscle-
rosis, it also enhances fibrinolytic procedures within the en-
dothelial environment. CRP increases plasminogen activator 
inhibitor-1 mRNA through induction of the NF-kB signal-
ling  pathway  [50]  and  downregulates  endothelial  tissue 
plasminogen activator, a serine protease that is responsible 
for fibrinolysis. This biochemical process is orchestrated by 
TNF-alpha  and  IL-1b  [51].  Other  important  atherogenic 
properties of CRP include CRP-induced oxidative stress via 
overproduction  of  reactive  oxygen  species  [52].  Reactive 
oxygen species in the endothelium enhance degradation of 
eNOS via eNOS uncoupling and subsequent increase in su-
peroxide [53]. In general, superoxide reacts rapidly with NO, 
forming peroxynitrite which significantly impairs NO bioac-
tivity [54] and deteriorates endothelial function.  
  TNF-alpha has direct effects on endothelial permeability 
by  altering  the  distribution  of  endothelial  cadherin-catenin 
and  inhibiting  the  re-structure  of  F-actin  fibers  [55].  This 
procedure may enable monocyte transmigration into the en-
dothelium and amplify the cascade of procedures that favor 
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thermore,  the  proliferation  of  macrophages  and  increased 
formation of foam cells enhances secretion of TNF-alpha in 
the endothelium, perpetuating this vicious atherogenic cycle 
[3].  TNF-alpha  also  upregulates  membrane  expression  of 
vascular cell adhesion molecule-1 [56], which plays a well 
established role  in atherosclerosis [57] and it precedes the 
development of thickened intima with foam cell lesions [58]. 
Apart from these in vitro observations, increased expression 
of serum TNF-alpha has been found in patients with athero-
sclerotic complications in population studies [59, 60]. In RA 
patients, TNF-alpha  enhances prothrombotic states such as 
dyslipidemia  [61],  but,  most  importantly,  pooled  evidence 
reveals that anti-TNF-alpha treatment may be in part respon-
sible for reducing the risk for CVD events in RA [62]. Re-
cent  studies  also  reveal  that  TNF-alpha  is  involved  in  the 
more advanced processes of atherosclerosis, specific to for-
mation of an advanced lesion via the inhibition of endothe-
lial  progenitor  cells  [63].  In  RA  patients,  endothelial  pro-
genitor cell numbers are decreased compared to the healthy 
population [63], a phenomenon which reverses via blockade 
of TNF-alpha [64]. 
  Inflammation in RA associates with dramatic increases of 
IL-6,  IL-1  and  TNF-alpha  levels,  which  can  trigger  the 
acute-phase response resulting in high CRP, and have direct 
effects on the endothelium that may enhance atherosclerotic 
processes. As such, uncontrolled inflammation is thought to 
be  amongst  the  prime  factors  involved  in  the  accelerated 
atherosclerosis in RA [1, 2].  
THE  EFFECTS  OF  EXERCISE  ON  VASCULAR  
BIOLOGY 
  Increasing physical activity has been identified as one of 
the  most  important  non-pharmacological  interventions  in 
both  preventing  and  rehabilitating  patients  with  non-
communicable  chronic  diseases  such  as  CVD.  This  is  
because  exercise  reverses  endothelial  dysfunction  and  has 
important  anti-atherogenenic  and  anti-inflammatory  effects 
(Fig. 1). Most importantly, even compared to standardized 
interventional  strategies,  exercise  may  improve  survival  at 
lower treatment costs [65].  
Endothelial Function and Exercise 
  Exercise  exerts  significant  effects  on  the  endothelial  
system,  both  acutely  and  in  the  long  term.  These  stimuli  
intervene and beneficially modify endothelial cell phenotype 
[17]. The acute effects of exercise are characterized by sig-
nificant increase  in blood flow pertaining  to  the  increased 
metabolic demands of the exercizing muscles and are closely 
related  to  the  muscle  fibre  type  recruitment  (slow  or  fast 
twitch) as well as the duration and intensity of exercise [66]. 
The  major  mechanism  responsible  for  exercise-induced  
hyperaemia  is  endothelial  NO  [67]  and  occurs  due  to  the 
increased endothelial eNOS protein expression [68] as well 
as eNOS activation via Akt phosphorylation [69]. Exercise 
acutely increases local expression of endothelial progenitor 
cells (endothelial repair) as well as cultured/circulating angi-
ogenic  cells  which  promote  angiogenesis  and  endothelial 
growth  [70].  Shear  stress  which  is  the  result  of  exercise-
induced  blood  flow  enhances  intracellular  mechanisms 
which  increase  eNOS  transcription  and  upregulate  anti-
oxidative  mechanisms.  Specifically,  tyrosine  kinase  c-Src 
acts to increase eNOS and extracellular superoxide dismu-
tase  expression,  both  of  which  relate  to  better  endothelial 
function [71]. In addition, it has been well-established that 
shear stress increases the expression of PG I2, a vasodilator 
and inhibitor of platelet aggregation [72]. Furthermore, vas-
cular  endothelial  growth  factor,  which  regulates  capillary 
supply  and  exercise-induced  angiogenesis,  is  significantly 
increased  in  response  to  exercise  in  both  untrained  and 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The effects of physical activity on endothelial function, atherosclerosis and inflammation. 
Exercise  Anti-Atherogenic Effects 
Anti-Inflammatory Effects 
Reverses Endothelial Dysfunction 
  Increased Blood Flow 
  Increased eNOS 
  Improved anti-Oxidative Mechanisms 
  Increased Endothelial Progenitor Cells 
  Increased Prostaglandin 
  Increased Vascular Endothelial Growth 
Factor 
  Increased eNOS 
  Decreased Endothelin-1 
  Increased anti-Oxidative Capacity 
  Decreased adhesion molecules 
  Decreased selectins 
  Decreased monocyte chemoattractant 
protein 1 
  Decreased C-Reactive Protein 
  Reduced Adipose Tissue Size 
  Decreased expression of pro-inflammatory 
cytokines 
  Anti-inflammatory action of interleukin-6 92    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Metsios et al. 
trained  individuals  [73].  In  the  long  term,  the  above  
mentioned  physiological  responses  promote  vascular  
remodelling,  a  necessary  adaptation  for  improved  oxygen 
exchange  and  blood  flow  delivery  [74].  These  long-term 
improvements are characterized by improved NO bioavail-
ability and/or endothelium-dependent vasodilation that may 
even  reverse  age-related  vascular  deterioration  [75,  76].  
Improved endothelium-dependent vasodilation in response to 
long-term  exercise  is  a  consistent  finding  in  both  healthy 
[77] and disease populations [78].  
Anti-Atherogenic Effects of Exercise 
  Acutely,  due  to  exercise-induced  shear  stress,  eNOS 
mRNA expression increases while ET-1 decreases [79, 80], 
while  concomitant  changes  involve  down-regulation  of  
vascular  cell  adhesion  molecule  1  [81].  Oxidative  stress  
accelerates  atherogenesis  via  oxidation  of  retained  low-
density lipoprotein, enhancing formation of foam cells [3]. 
An  important  long-term  adaptation  to  exercise  is  the  im-
provement in the anti-oxidative capacity of the human body, 
i.e. resistance to oxidative stress [82]. In particular, the en-
zymes catalase and superoxide dismutase which decompose 
reactive oxygen species are significantly increased as a result 
of  habitual  physical  activity  [83].  Increased  eNOS  in  the 
endothelium increases anti-oxidant molecules such as super-
oxide dismutases 1 and 3 and angiotensin receptor type 2 and 
decreases  oxidative  molecules  such  as  NADPH  oxidase  
and angiotensin receptor type 1 [84]. Endothelial expression 
of adhesion  molecules, selectins and  MCP-1, all of which 
promote atherosclerosis, also decreases [85].  
Anti-Inflammatory Effects of Exercise  
  Physical activity and/or moderate intensity exercise have 
profound anti-inflammatory effects in the healthy population 
as well as patients with chronic diseases [86]. In population-
based studies, regular physical activity is consistently associ-
ated with a reduction in CRP levels [87, 88] which is also the 
case  in  patients  with  RA  [89,  90].  The  exact  mechanisms 
whereby  regular  exercise  reduces  CRP  have  not  yet  been 
fully elucidated, but it seems that this association may exist 
via exercise-induced reduction in hypertension, triglycerides, 
and  apolipoproteins,  factors  which  are  directly  related  to 
CRP concentration [91]. Most importantly, exercise reduces 
adipose tissue which is largely responsible for secretion of 
IL-6, a major trigger for hepatic production of CRP [92, 93]. 
However,  these  are  physiological  responses  of  moderate 
physical  activity/exercise,  whereas  strenuous  exercise  
may acutely promote an inflammatory response. CRP may 
increase immediately after prolonged strenuous exercise but 
returns to basal levels after approximately 48 hours, while 
this proportionate rise in CRP depends on the intensity of the 
exercise and the subsequent exercise-induced muscle dam-
age [94, 95].  
  Recent advances in muscle physiology reveal that muscle 
tissue is responsible for the production of myokines (muscle 
cytokines) suggesting that muscle is also an endocrine organ 
[96].  Muscle  contractions  regulate  expression  of  specific 
cytokines  such  as  IL-6,  -8,  -10,  and  -15,  as  well  as  IL-1  
receptor antagonist and TNF-alpha [96-98]. It is thought that, 
although IL-6 is predominantly a pro-inflammatory cytokine, 
it may also have under certain circumstances anti-inflamma- 
tory properties [99]. In that light, and based on the fact that 
IL-6 increases exponentially with acute exercise up to 100 
times compared to resting levels and returns to resting levels 
post-exercise [100],  it has been suggested  that IL-6  is the 
most important cytokine that induces the anti-inflammatory 
effects of exercise [96]. In contrast, pro-inflammatory cyto-
kines IL-1b and TNF-alpha do not generally increase in re-
sponse to moderate  intensity  exercise [101], whereas  anti-
inflammatory  cytokines  such  as  IL-1ra  and  IL-10,  signifi-
cantly increase [99, 102]. Interestingly, in response to regu-
lar  exercise,  IL-6  exerts  its  anti-inflammatory  effects  by  
primarily  inhibiting  the  expression  of  TNF-alpha  [99].  
Data have demonstrated that IL-6 inhibits lipopolysacharide-
induced  TNF-alpha  in  human  blood  mononunclear  cells 
[103], whereas TNF-alpha levels are overexpressed in IL-6 
deficient mice [104]. Recently, the transcriptional coactiva-
tor  PGC1a  has  also  attracted  attention  as  it  suppresses  
various inflammatory responses and regulates the effects of 
exercise [105] by coactivating transcription factors involved 
in  biogenesis  of  mitochondria,  oxidative  phosphorylation 
and  fatty  acid  oxidation  [106,  107].  All  these  biological 
changes in cytokine expression in response to exercise, lead 
to beneficial long-term effects. Indeed, a consistent finding 
in the literature is that regular exercise relates to decreased 
systemic inflammation in both healthy and diseased popula-
tions [88, 89, 108, 109].  
EFFECTS OF EXERCISE ON CVD IN RA 
  The extensive damage of the joint structures in RA has 
initially  led  to  the  notion  that  RA  patients  should  rest,  as 
exercise may enhance joint damage [110]. However, during 
the last decade substantial evidence deriving from random-
ised trials reveals that exercise inhibits the progression of the 
disease and improves both wellbeing and functional ability 
of  RA  patients  [90].  This  is  due  to  normal  physiological 
processes which develop as a result of exercise training such 
as the improved muscle co-ordination and hypertrophy, re-
duced  fat  mass  and  better  immune  function.  Patients  that 
indeed have to refrain from specific exercises are those with 
extensive  structural  damage;  in  this  occasion  load  of  the 
damaged joints has to be avoided and can be replaced with 
alternative types of exercise. The beneficial effects of differ-
ent exercise training types on disease activity and severity 
have been confirmed several times by various studies [110, 
111] and hence, based on these evidence, exercise has now 
been  incorporated  in  the  management  of  RA  [112].  It  is, 
therefore  imperative  that  RA  patients  embark  on  exercise 
training  programmes.  Although  exercise  is  beneficial,  in-
creasing physical activity in this population may prove diffi-
cult [113] perhaps due to the frequent advice from rheuma-
tology specialists to RA patients, that exercise may exacer-
bate disease symptoms [114]. However, data from published 
studies  [110]  of  excellent  quality  as  well  as  anecdotal  
evidence, reveal that RA patients should and can exercise at 
high intensities, and this is beneficial for various outcomes 
of this chronic disease. Moreover, studies have collectively 
shown  that  overall  the  adherence  rates  in  exercise  pro-
grammes  can  be  high,  presumably  due  to  the  fact  that  
the significant improvements achieved via exercise promote 
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  In  a  systematic  review  on  exercise,  CVD  and  RA,  we 
found  that,  surprisingly,  no  studies  have  investigated  the 
effects of exercise on CVD outcomes in this population [90]. 
However, given the ample evidence of the beneficial effects 
of  physical  activity/exercise  on  inhibiting  disease  progres-
sion and improving disease outcomes, we have proposed a 
model in which exercise should be incorporated in the man-
agement of the disease in order to prevent CVD, which is 
highly prevalent in this population. In this model, we suggest 
that effective treatment and control of inflammation should 
precede involvement in exercise in order to prohibit further 
damage and discomfort for the RA patient. Various drugs are 
available for patients with RA, including biological agents 
such as  TNF-alpha, which target different biological path-
ways for inhibiting disease progression. Overall, medication 
strategies are effective in ameliorating disease activity (i.e. 
reduced  expression  of  pro-inflammatory  cytokines  and 
CRP), a phenomenon that is also apparent as a response to 
exercise  training.  Nevertheless, given the  lack of evidence 
regarding the effects of exercise on RA, potential changes in 
medication should always be based on robust clinical out-
comes and patient feedback.  
  Exercise involvement and/or increased physical activity 
are included in the management of many chronic diseases. In 
RA,  where  patients  experience  increased  prevalence  of 
CVD, exercise may be even more important due to its anti-
atherogenic  and  anti-inflammatory  effects  [17,  99].  The  
majority of studies on RA and exercise investigated the ef-
fects  of  physical  activity/exercise  regimens  on  improving 
RA-related disease outcomes. We have recently shown that 
physically inactive RA patients have worse CVD risk profile 
compared to physically active patients. In this cross-sectional 
study, we have investigated classical and novel risk factors, 
the prevalence of established CVD as well as  the risk  as-
sessment of developing CVDs in physically active as well as 
inactive RA patients. Regarding the novel CVD risk factors, 
our results revealed that parameters associated with vascular 
function  (e.g.  von  Willebrand  factor),  fibrinolysis  athero-
genesis (lipoproteins), pro-inflammatory cytokines, and CRP 
were  markedly  improved  in  patients  who  demonstrated  
increased  levels  of  physical  activity  [89].  However,  more 
research  is  required  in  order  to  investigate  the  potential  
associations of exercise on vascular function and CVD risk 
in this population as well as the mechanisms that underlie 
these associations.  
CONCLUSION 
  Evidence from basic research supports a clear association 
between inflammation, vascular dysfunction and atheroscle-
rosis. In RA, although evidence exists to support this asso-
ciation for atherosclerosis, the results are equivocal at least 
for endothelial dysfunction, potentially due to the differences 
in the methodological designs that do not take into account 
important  factors  that  could  influence  endothelial  function 
and atherosclerosis in RA. In addition, exercise has a protec-
tive  effect  via  inhibiting  the  expression  of  inflammatory 
markers and their effects on both endothelial dysfunction and 
promotion  of  atherosclerosis.  Future  studies  in  RA  should 
specifically  investigate  the  effects  of  exercise  regimes  on 
endothelial function and atherosclerosis both  in population 
studies and at a molecular level.  
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